In summary, upregulated ALKBH5 plays an oncogenic role in HNSCC by inhibiting RIG-I-mediated IFNα secretion via the IKKε/TBK1/IRF3 pathway, which ultimately reduces immune-killing cell infiltration and promotes tumor progression (Fig. 8e). Here, IRF3 is linked to head and neck squamous cell carcinoma.